MedCap (Q4 initial take): A Slight Beat on High Growth Forecast - Redeye

Redeye provides its initial take on MedCap’s Q4 2025 report, which came in broadly in line with our estimates, with a slight beat in revenues and adjusted EBITA. Medtech outperformed while Speciality Pharma lagged our estimates, although all sectors grew Q/Q and Y/Y. Similarly, Medtech increased its adjusted EBITA margin while Specialty Pharma's decreased it compared with Q3 2025.

Länk till analysen i sin helhet: https://www.redeye.se/research/1147470/medcap-q4-initial-take-a-slight-beat-on-high-growth-forecast?utm_source=finwire&utm_medium=RSS